On this page
Long QT syndrome type 1
LQTS1 can lead to a prolonged QT interval on an electrocardiogram (ECG), which increases the risk of dangerous arrhythmias. It typically presents with symptoms such as fainting or seizures, often triggered by exercise or emotional stress.
Overview
Long QT syndrome type 1 (LQTS1) is a condition that affects the heart's electrical activity. In a healthy heart, each beat is precisely timed by electrical signals that cause the heart muscle to contract and then relax. The 'QT interval' seen on an electrocardiogram (ECG) represents the time it takes for the heart's ventricles (lower chambers) to contract and then recover, or repolarise [PMID:33678077]. In LQTS1, this recovery phase is abnormally long. This can make the heart vulnerable to developing fast, irregular heart rhythms, known as arrhythmias, particularly a type called Torsades de Pointes.
While some individuals with LQTS1 may never experience symptoms, others may have episodes of fainting (syncope), seizures, or, in rare and severe cases, sudden cardiac arrest. These events are often triggered by physical activity, strong emotions, or sudden loud noises. LQTS1 is a genetic condition, meaning it is inherited through families. It is one of the most common forms of Long QT syndrome, affecting approximately 1 in 2,500 people.
Symptoms & clinical features
The symptoms of LQTS1 can vary significantly, even within the same family. Some people with the condition may experience no symptoms at all, while others may have recurrent episodes. The most common symptom is fainting, often without warning. These fainting spells are usually triggered by physical exertion, such as swimming or other sports, or by strong emotional reactions like fright or anger [PMID:33678077].
Other potential symptoms include seizures, which may occur due to reduced blood flow to the brain during an arrhythmia, and heart palpitations, where a person feels their heart is racing or beating irregularly. In some severe cases, LQTS1 can lead to sudden cardiac arrest, which is a life-threatening emergency where the heart abruptly stops beating effectively. Symptoms typically begin during childhood or adolescence, but they can also appear later in life.
Video: Genetics 101
Affected organs
LQTS1 primarily affects the heart. The condition impacts the heart's electrical system, specifically the ion channels responsible for the flow of potassium ions in and out of heart muscle cells. This disruption prolongs the repolarisation phase of the cardiac action potential, leading to the characteristic long QT interval visible on an ECG. While the heart is the main organ affected, some individuals with specific genetic changes linked to LQTS1 may also experience hearing problems, though this is less common in typical LQTS1.
Risks & severity
The severity of LQTS1 can range from asymptomatic to life-threatening. The primary risk associated with LQTS1 is the development of dangerous ventricular arrhythmias, such as Torsades de Pointes, which can lead to fainting, seizures, or sudden cardiac arrest. These events are often triggered by specific stimuli, with exercise and emotional stress being particularly common triggers for LQTS1 [PMID:33678077].
The lifetime risk of cardiac events varies among individuals with LQTS1 and can be influenced by factors such as the specific genetic variant, the degree of QT prolongation, and family history. Generally, untreated individuals with LQTS1 have a higher risk of cardiac events. The age of onset for symptoms is highly variable, but many individuals experience their first symptoms during childhood or adolescence. However, some may remain asymptomatic until adulthood, or never develop symptoms at all. Accurate diagnosis and appropriate management can significantly reduce these risks.
Genetic causes
Long QT syndrome type 1 is caused by pathogenic variants in the KCNQ1 gene. The KCNQ1 gene provides instructions for making a protein that is a crucial component of a specific type of potassium channel in heart muscle cells. These channels are responsible for controlling the flow of potassium ions across the cell membrane, which is essential for the heart to relax and reset after each beat (repolarisation).
When there is a pathogenic variant in KCNQ1, the potassium channels do not function correctly. This can lead to a reduced outflow of potassium ions from the heart cells, which in turn prolongs the repolarisation phase. This extended repolarisation is what results in the prolonged QT interval observed on an ECG and increases the heart's susceptibility to dangerous arrhythmias. The normal function of the KCNQ1 protein is vital for maintaining the heart's regular rhythm [PMID:19187356].
- KCNQ1 potassium voltage-gated channel subfamily Q member 1The KCNQ1 gene provides instructions for making a protein that forms a critical part of voltage-gated potassium channels, which are essential for regulating electrical signals in the heart and inner ear.
Inheritance pattern
LQTS1 is inherited in an autosomal dominant pattern. This means that a person only needs to inherit one copy of the altered KCNQ1 gene from one parent to develop the condition. If a parent has LQTS1, there is a 50% chance with each pregnancy that their child will inherit the pathogenic variant and therefore also have LQTS1.
Individuals who inherit the altered gene may or may not experience symptoms, as there can be variability in how the condition affects different people, even within the same family. It is important for family members of someone diagnosed with LQTS1 to be offered genetic counselling and, where appropriate, genetic testing, as they may also be at risk of having the condition.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
The diagnosis of LQTS1 typically involves a combination of clinical evaluation, electrocardiogram (ECG) findings, and genetic testing. A cardiologist will assess an individual's symptoms, family history of unexplained fainting, seizures, or sudden death. The hallmark of diagnosis is a prolonged QT interval on an ECG, which measures the electrical activity of the heart. Sometimes, an exercise ECG (stress test) or a Holter monitor (24-hour ECG recording) may be used to uncover QT prolongation that is not apparent on a resting ECG or to identify arrhythmias.
Genetic testing confirms the diagnosis by identifying a pathogenic variant in the KCNQ1 gene. This is often carried out as part of the NHS Genomic Medicine Service (GMS) under relevant R-codes, such as R133 for inherited cardiac conditions. A referral to clinical genetics services is typically made by a cardiologist once LQTS is suspected. Genetic counselling is an integral part of this process, providing information and support to individuals and families considering or undergoing genetic testing.
Management & lifestyle
Management for LQTS1 focuses on reducing the risk of arrhythmias and preventing sudden cardiac events. While there is no cure, various strategies can effectively manage the condition. Beta-blockers are often the first-line treatment, as they help to slow the heart rate and shorten the QT interval, thereby reducing the risk of arrhythmias [PMID:22081512].
Lifestyle modifications are also important; individuals are generally advised to avoid strenuous exercise, loud noises, and certain medications that can further prolong the QT interval. In some cases, particularly for those who have experienced severe symptoms or who remain at high risk despite medication, an implantable cardioverter-defibrillator (ICD) may be recommended. This device can detect life-threatening arrhythmias and deliver an electrical shock to restore a normal heart rhythm. Regular follow-up with a cardiologist is essential to monitor the condition and adjust management as needed.
UK care pathway
In the UK, individuals suspected of having LQTS1 typically enter the NHS Genomic Medicine Service (GMS) pathway. This often begins with a referral from a GP to a cardiologist, who will conduct initial assessments, including ECGs. If an inherited cardiac condition is suspected, the cardiologist may then refer the individual to a clinical genetics service.
Genetic testing for LQTS1 is available through the GMS, often utilising specific R-codes from the National Genomic Test Directory (e.g., R133 for inherited cardiac conditions) to ensure appropriate testing is performed. Genetic counsellors play a vital role in this pathway, providing detailed information about the condition, inheritance patterns, testing options, and emotional support to affected individuals and their families. They also assist in cascade testing for at-risk relatives.
Frequently asked questions
What activities should I avoid if I have LQTS1?
If you have LQTS1, it's generally recommended to avoid strenuous exercise, especially competitive sports, as well as activities that involve sudden loud noises or extreme emotional stress. Your cardiologist will provide specific advice tailored to your individual risk profile and treatment plan.
Can LQTS1 be cured?
Currently, there is no cure for LQTS1. However, the condition can be effectively managed with medication, such as beta-blockers, and lifestyle adjustments. In some cases, medical devices like implantable cardioverter-defibrillators (ICDs) can also help prevent serious complications.
How often do I need to see a doctor if I have LQTS1?
Regular follow-up appointments with a cardiologist are essential for individuals with LQTS1. The frequency of these appointments will depend on your symptoms, treatment plan, and overall risk, but typically involves annual reviews unless otherwise advised by your specialist.
Are there medications I should avoid with LQTS1?
Yes, certain medications can prolong the QT interval and should be avoided if you have LQTS1. This includes some antibiotics, antihistamines, antidepressants, and antiarrhythmic drugs. Always inform your doctor and pharmacist about your LQTS1 diagnosis before starting any new medication.
What should I tell my family about my LQTS1 diagnosis?
It is important to inform your close relatives (parents, siblings, children) about your LQTS1 diagnosis, as they may also be at risk of carrying the genetic variant. They should be encouraged to speak to their GP about referral for cardiac evaluation and genetic counselling to determine their own risk.
References
- Schwartz PJ, Moreno C, Kotta MC. Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region. European heart journal. 2021. PMID: 34505893
- Bileisiene N, Shelest A, Petraityte G. Long QT syndrome type 1: clinical and functional characterization of KCNQ1 variant c.1111G > C. BMC cardiovascular disorders. 2025. PMID: 41299264
- Zhong L, Yan Z, Jiang D. Targeting the I(Ks) Channel PKA Phosphorylation Axis to Restore Its Function in High-Risk LQT1 Variants. Circulation research. 2024. PMID: 39166328
- Wu J, Ding WG, Horie M. Molecular pathogenesis of long QT syndrome type 1. Journal of arrhythmia. 2016. PMID: 27761162
- Marstrand P, Almatlouh K, Kanters JK. Long QT syndrome type 1 and 2 patients respond differently to arrhythmic triggers: The TriQarr in vivo study. Heart rhythm. 2021. PMID: 32882399
- Morita H. They Are Not Monozygotic Twins - Long QT Syndrome Type 1 (LQT1) and Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Circulation journal : official journal of the Japanese Circulation Society. 2018. PMID: 30089744
- Nademanee K. Exercise and vagal reflex in long QT syndrome type 1. Journal of the American College of Cardiology. 2012. PMID: 23158535
- Ziupa D, Menza M, Koppermann S. Electro-mechanical (dys-)function in long QT syndrome type 1. International journal of cardiology. 2019. PMID: 30017522